Protocol Ledger

NCT05386550 · Phase III · TERMINATED

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Interventional Phase III clinical trial protocol NCT05386550 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-06 Enrollment: 166 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05386550
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)166 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05386550
Protocol FieldVerified Registry Value
NCT IdentifierNCT05386550
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment166 participants (ACTUAL)
Registered Start Date2022-10-06
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05386550
Hospital Research SiteLocationSite Profile
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Barbara Ann Karmanos Cancer InstituteDetroit, MIOpen Hospital Dossier ->
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI